Is It Safe to Stop Anti-PD-1 Immunotherapy in Patients With Metastatic Melanoma Who Achieve a Complete Response?
作者信息
Davies Michael A
机构信息
Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX.
出版信息
J Clin Oncol. 2020 May 20;38(15):1645-1647. doi: 10.1200/JCO.20.00136. Epub 2020 Feb 25.
Abstract
摘要
相似文献
1
Is It Safe to Stop Anti-PD-1 Immunotherapy in Patients With Metastatic Melanoma Who Achieve a Complete Response?对于获得完全缓解的转移性黑色素瘤患者，停止抗程序性死亡蛋白1（PD-1）免疫治疗是否安全？
J Clin Oncol. 2020 May 20;38(15):1645-1647. doi: 10.1200/JCO.20.00136. Epub 2020 Feb 25.
2
Immunotherapy-induced sarcoidosis in patients with melanoma treated with PD-1 checkpoint inhibitors: Case series and immunophenotypic analysis.接受PD-1检查点抑制剂治疗的黑色素瘤患者中免疫疗法诱导的结节病：病例系列及免疫表型分析
Int J Rheum Dis. 2017 Sep;20(9):1277-1285. doi: 10.1111/1756-185X.13076. Epub 2017 May 8.
3
Immunotherapy comes of age in octagenarian and nonagenarian metastatic melanoma patients.免疫疗法在 80 岁及 90 岁以上转移性黑色素瘤患者中崭露头角。
Eur J Cancer. 2019 Feb;108:61-68. doi: 10.1016/j.ejca.2018.12.012. Epub 2019 Jan 14.
4
The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma.转移性黑色素瘤免疫检查点抑制剂所致内分泌病的谱、发病率、动力学及管理
Eur J Endocrinol. 2018 Feb;178(2):173-180. doi: 10.1530/EJE-17-0810. Epub 2017 Nov 29.
5
Investigating the role of immunotherapy in advanced/recurrent female genital tract melanoma: a preliminary experience.探讨免疫疗法在晚期/复发性女性生殖道黑色素瘤中的作用：初步经验。
J Gynecol Oncol. 2019 Nov;30(6):e94. doi: 10.3802/jgo.2019.30.e94.
6
Using a cancer registry to capture signals of adverse events following immune and targeted therapy for melanoma.利用癌症登记系统捕捉黑色素瘤免疫治疗和靶向治疗后的不良事件信号。
Int J Clin Pharm. 2018 Aug;40(4):852-861. doi: 10.1007/s11096-018-0665-1. Epub 2018 Jun 2.
7
Anti-PD-1 immunotherapy in advanced metastatic melanoma: State of the art and future challenges.抗 PD-1 免疫疗法治疗晚期转移性黑色素瘤：现状与未来挑战。
Life Sci. 2020 Jan 1;240:117093. doi: 10.1016/j.lfs.2019.117093. Epub 2019 Nov 21.
8
Durable complete responses off all treatment in patients with metastatic malignant melanoma after sequential immunotherapy followed by a finite course of BRAF inhibitor therapy.转移性恶性黑色素瘤患者在序贯免疫治疗后接受有限疗程的BRAF抑制剂治疗后，停止所有治疗仍有持久的完全缓解。
Cancer Biol Ther. 2015;16(5):662-70. doi: 10.1080/15384047.2015.1026507.
9
Microsatellite Instability Predicts Response to Anti-PD1 Immunotherapy in Metastatic Melanoma.微卫星不稳定性预测转移性黑色素瘤对抗PD1免疫疗法的反应。
Acta Dermatovenerol Croat. 2018 Dec;26(4):341-343.
10
[Primary central nervous system lymphoma following immunotherapy for metastatic melanoma].转移性黑色素瘤免疫治疗后发生的原发性中枢神经系统淋巴瘤
Ann Dermatol Venereol. 2019 Oct;146(10):634-639. doi: 10.1016/j.annder.2019.04.021. Epub 2019 May 20.
引用本文的文献
1
Discontinuation of immune checkpoint inhibitors for reasons other than disease progression and the impact on relapse and survival of advanced melanoma patients. A systematic review and meta-analysis.因疾病进展以外的原因停用免疫检查点抑制剂及其对晚期黑色素瘤患者复发和生存的影响：一项系统评价和荟萃分析
Front Immunol. 2025 Jan 31;16:1524945. doi: 10.3389/fimmu.2025.1524945. eCollection 2025.
2
Complete response of a metastatic microsatellite-stable gastric cancer after neoadjuvant chemoimmunotherapy: should we still operate? A case report and review of the literature.新辅助化疗免疫治疗后转移性微卫星稳定型胃癌的完全缓解：我们仍应进行手术吗？一例病例报告及文献综述
Front Oncol. 2024 Nov 20;14:1440046. doi: 10.3389/fonc.2024.1440046. eCollection 2024.
3
Longitudinal analysis of the gut microbiota during anti-PD-1 therapy reveals stable microbial features of response in melanoma patients.抗 PD-1 治疗期间肠道微生物组的纵向分析揭示了黑色素瘤患者应答的稳定微生物特征。
Cell Host Microbe. 2024 Nov 13;32(11):2004-2018.e9. doi: 10.1016/j.chom.2024.10.006. Epub 2024 Oct 30.
4
Progression-Free Survival and Treatment-Free Interval in Head and Neck Cancer with Long-Term Response to Nivolumab: Timing of Active Discontinuation.对头颈部癌患者使用纳武单抗长期缓解后的无进展生存期和无治疗间期：主动停药时机
Cancers (Basel). 2024 Jul 12;16(14):2527. doi: 10.3390/cancers16142527.
5
Discontinuation of anti‑programmed cell death protein 1 immune checkpoint inhibition after complete remission in head and neck squamous cell carcinoma: A case report and literature review.头颈部鳞状细胞癌完全缓解后停用抗程序性细胞死亡蛋白1免疫检查点抑制剂：一例报告及文献综述
Oncol Lett. 2023 Sep 27;26(5):489. doi: 10.3892/ol.2023.14076. eCollection 2023 Nov.
6
MicroRNA-708 emerges as a potential candidate to target undruggable NRAS.MicroRNA-708 作为一种潜在的候选药物，可针对不可成药的 NRAS 进行靶向治疗。
PLoS One. 2023 Apr 21;18(4):e0284744. doi: 10.1371/journal.pone.0284744. eCollection 2023.
7
Shaping the Future of Immunotherapy Targets and Biomarkers in Melanoma and Non-Melanoma Cutaneous Cancers.塑造黑色素瘤和非黑色素瘤皮肤癌免疫治疗靶点和生物标志物的未来。
Int J Mol Sci. 2023 Jan 9;24(2):1294. doi: 10.3390/ijms24021294.
8
Checkpoint Inhibitors Immunotherapy in Metastatic Melanoma: When to Stop Treatment?转移性黑色素瘤中的检查点抑制剂免疫疗法：何时停止治疗？
Biomedicines. 2022 Sep 28;10(10):2424. doi: 10.3390/biomedicines10102424.
9
What is the optimal duration of immune checkpoint inhibitors in malignant tumors?免疫检查点抑制剂在恶性肿瘤中的最佳持续时间是多久？
Front Immunol. 2022 Sep 26;13:983581. doi: 10.3389/fimmu.2022.983581. eCollection 2022.
10
Anti-PD-1: When to Stop Treatment.抗 PD-1：何时停止治疗。
Curr Oncol Rep. 2022 Jul;24(7):905-915. doi: 10.1007/s11912-022-01264-6. Epub 2022 Mar 26.
本文引用的文献
1
Long-Term Outcomes and Responses to Retreatment in Patients With Melanoma Treated With PD-1 Blockade.接受 PD-1 阻断治疗的黑色素瘤患者的长期结果和再治疗应答。
J Clin Oncol. 2020 May 20;38(15):1655-1663. doi: 10.1200/JCO.19.01464. Epub 2020 Feb 13.
2
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.纳武利尤单抗联合伊匹木单抗治疗晚期黑色素瘤的 5 年生存数据
N Engl J Med. 2019 Oct 17;381(16):1535-1546. doi: 10.1056/NEJMoa1910836. Epub 2019 Sep 28.
3
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study.帕博利珠单抗对比伊匹单抗用于晚期黑色素瘤（KEYNOTE-006）：一项开放标签、多中心、随机、对照、III 期研究的 5 年随访后结果。
Lancet Oncol. 2019 Sep;20(9):1239-1251. doi: 10.1016/S1470-2045(19)30388-2. Epub 2019 Jul 22.
4
Safety, Efficacy, and Patient-Reported Health-Related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer, Including Patients Aged 70 Years or Older or with Poor Performance Status (CheckMate 153).纳武利尤单抗治疗晚期非小细胞肺癌患者的安全性、疗效以及患者报告的健康相关生活质量和症状负担，包括 70 岁或以上或体能状态不佳的患者（CheckMate 153）。
J Thorac Oncol. 2019 Sep;14(9):1628-1639. doi: 10.1016/j.jtho.2019.05.010. Epub 2019 May 20.
5
Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 Antibody.分析接受程序性死亡蛋白 1 或程序性死亡配体 1 抗体治疗的患者不良事件与结局之间的关联。
J Clin Oncol. 2019 Oct 20;37(30):2730-2737. doi: 10.1200/JCO.19.00318. Epub 2019 May 22.
6
Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma.抗 PD-1 抗体治疗在无疾病进展或治疗限制毒性的情况下停药：晚期黑色素瘤的临床结局。
Ann Oncol. 2019 Jul 1;30(7):1154-1161. doi: 10.1093/annonc/mdz110.
7
Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001.KEYNOTE-001 研究中接受派姆单抗治疗的晚期黑色素瘤患者的 5 年生存结果。
Ann Oncol. 2019 Apr 1;30(4):582-588. doi: 10.1093/annonc/mdz011.
8
Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.新辅助免疫检查点阻断治疗高危可切除黑色素瘤。
Nat Med. 2018 Nov;24(11):1649-1654. doi: 10.1038/s41591-018-0197-1. Epub 2018 Oct 8.
9
Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma.帕博利珠单抗停药后转移性黑色素瘤患者持久完全缓解
J Clin Oncol. 2018 Jun 10;36(17):1668-1674. doi: 10.1200/JCO.2017.75.6270. Epub 2017 Dec 28.
10
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma.伊匹单抗治疗不可切除或转移性黑色素瘤的II期和III期试验长期生存数据的汇总分析
J Clin Oncol. 2015 Jun 10;33(17):1889-94. doi: 10.1200/JCO.2014.56.2736. Epub 2015 Feb 9.
Zotero 插件